SONN vs. PHXM, TNXP, KA, SHPH, ATHE, OBSV, WENA, CHRO, TCBP, and TCRT
Should you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include PHAXIAM Therapeutics (PHXM), Tonix Pharmaceuticals (TNXP), Kineta (KA), Shuttle Pharmaceuticals (SHPH), Alterity Therapeutics (ATHE), ObsEva (OBSV), ANEW Medical (WENA), Chromocell Therapeutics (CHRO), TC Biopharm (TCBP), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical products" industry.
PHAXIAM Therapeutics (NASDAQ:PHXM) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.
0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Sonnet BioTherapeutics has a consensus price target of $30.00, suggesting a potential upside of 3,388.37%. Given PHAXIAM Therapeutics' higher possible upside, analysts clearly believe Sonnet BioTherapeutics is more favorable than PHAXIAM Therapeutics.
Sonnet BioTherapeutics received 18 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users.
PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
PHAXIAM Therapeutics has a net margin of 0.00% compared to PHAXIAM Therapeutics' net margin of -11,187.19%. Sonnet BioTherapeutics' return on equity of 0.00% beat PHAXIAM Therapeutics' return on equity.
In the previous week, Sonnet BioTherapeutics had 4 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 4 mentions for Sonnet BioTherapeutics and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.41 beat Sonnet BioTherapeutics' score of 0.00 indicating that Sonnet BioTherapeutics is being referred to more favorably in the news media.
PHAXIAM Therapeutics has higher revenue and earnings than Sonnet BioTherapeutics.
Summary
Sonnet BioTherapeutics beats PHAXIAM Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Sonnet BioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sonnet BioTherapeutics Competitors List
Related Companies and Tools
Free SONN Stock Alerts